Alnylam Pharmaceuticals, Inc. has announced the U.S. Food and Drug Administration (FDA) approval of the supplemental new drug application (SNDA) for its RNAi therapeutic, Amvuttra® (vutrisiran). This ...
Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...
Pharmaceuticals announced moderated poster presentations of new data from the HELIOS-B Phase 3 clinical trial, which evaluated ...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitliatm (fitusiran), the sixth ...
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...
Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...
President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...
The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
The U.S. Food and Drug Administration has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback